DOC

From PsychonautWiki
Jump to: navigation, search
Summary sheet: DOC
DOC
DOC.svg
Chemical Nomenclature
Common names DOC
Substitutive name 2,5-Dimethoxy-4-chloroamphetamine
Systematic name 1-(4-Chloro-2,5-dimethoxy-phenyl)propan-2-amine
Class Membership
Psychoactive class Psychedelic
Chemical class Amphetamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 0.5 - 1 mg
Light 1 - 2 mg
Common 2 - 4 mg
Strong 4 - 6 mg
Heavy 6 mg +
Duration
Total 12 - 24 hours
Onset 1 - 2 hours
Come up 2 - 3 hours
Peak 6 - 12 hours
Offset 2 - 8 hours
After effects 6 - 24 hours



Insufflated
Dosage
Threshold 0.25 mg
Light 0.25 - 1 mg
Common 1 - 2 mg
Strong 2 - 3.5 mg
Heavy 3.5 mg +
Duration
Onset 1 - 5 minutes
Come up 10 - 30 minutes
Peak 2 - 6 hours
Offset 2 - 8 hours
After effects 2 - 24 hours






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

4-Chloro-2,5-dimethoxyamphetamine (also known as DOC) is a psychedelic substance of the amphetamine chemical class.

DOC was first synthesized by a team at the University of Alberta in 1972.[1] However, its usage in humans was not popularized until the 1991 publication PiHKAL ("Phenethylamines I Have Known And Loved") by Alexander Shulgin.[2] Preceding this, a 1989 forensic analysis of designer amphetamine samples identified DOC in Canadian drug seizures.[3]

Over the years DOC has come to be known as a highly dose-sensitive psychedelic that is often sold in powder form or on blotting paper and known for its long duration (over 12-24 hours), strong visual effects, a unique form of stimulation, and a significant body load.

Today, DOC is used as a recreational drug and an entheogen, rarely sold on the streets (unless in the form of misrepresented LSD) and almost exclusively obtained as a grey area research chemical through online vendors.

Along with its sensitive dose-response and unusually long duration, many reports also suggest that this substance may be overly difficult to use safely for those who are not already very experienced with hallucinogens. Therefore it is highly advised to approach this unusually dose-sensitive, and long-lasting psychedelic substance with the proper amount of precaution and harm reduction practices if choosing to use it.

History and culture

History icon.svg

This History and Culture section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

DOC was first synthesized by 1972 by Ronald Coutts and Jerry Malicky at the University of Alberta[4]. While human usage was popularized by the 1991 publication of its synthesis and pharmacology in PiHKAL ("Phenethylamines I Have Known And Loved")[2] by Alexander Shulgin, a 1989 forensic analysis of designer amphetamine samples identified DOC in Canadian drug seizures[5].

Chemistry

DOC or 4-chloro-2,5-dimethoxy-amphetamine, is a molecule of the substituted amphetamine class. Amphetamines are substituted phenethylamines containing a phenyl ring bound to an amino (NH2) group through an ethyl chain and a methyl group bound to the alpha carbon Rα. DOC contains methoxy functional groups OCH3 attached to carbons R2 and R5 and a chlorine atom attached to carbon R4 of the phenyl ring. DOC is the amphetamine analogue of the phenethylamine 2C-C.[6]

Pharmacology

Further information: Serotonergic psychedelic

DOC's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects
Child.svg

Visual effects
Eye.svg

Cognitive effects
User.svg

Multi-sensory effects
Gears.svg

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational DOC use do not seem to have been studied in any scientific context and the exact toxic dose is unknown.

Anecdotal evidence suggests that there are no negative health effects attributed to simply trying by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Medical literature reports multiple physical complications associated with the use of DOC. An individual's cause of death was reported as DOC toxicity and confirmed with GC-MS in the Journal of Analytical Toxicology.[7] Seizures have been associated with the use of DOC in another medical journal.[8]

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

DOC is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of DOC are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). DOC presents cross-tolerance with all psychedelics, meaning that after the consumption of DOC all psychedelics will have a reduced effect.

Dangerous interactions

Ambulance2.png

This dangerous interactions section is a stub.

As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it.

Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Legal status

  • Brazil - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[10]
  • Denmark: DOC is a Schedule I drug.[citation needed]
  • Finland: The possession, production and sale is illegal.[citation needed]
  • Israel: The possession, production and sale is illegal.[citation needed]
  • New Zealand: DOC is a Class C drug.[citation needed]
  • Germany: DOC is listed in Anlage I in Germany, making it illegal to buy, sell, or possess without a license.[citation needed]
  • Canada: DOC is Schedule I in Canada, making it illegal to sell, buy, or possess, without a valid legal exemption.[11]
  • United Kingdom: DOC is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.[12]
  • United States: DOC is technically not scheduled in the United States, but could be considered an analogue of DOM or DOB and may therefore be considered a Schedule I drug under the Federal Analogue Act.[citation needed]
  • Latvia: DOC is a Schedule I controlled substance.[13]
  • China - As of October 2015 DOC is a controlled substance in China.[14]

See also

External links

Discussion

References

  1. Coutts, Ronald T; Malicky, Jerry L. (1973). "The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM)". Canadian Journal of Chemistry, 1973, 51(9): 1402-1409, 10.1139/v73-210 | http://www.nrcresearchpress.com/doi/abs/10.1139/v73-210
  2. 2.0 2.1 http://www.erowid.org/library/books_online/pihkal/pihkal.shtml
  3. Brian A. Dawson & George A. Neville (1989) "Identification of Two New 'Designer' Amphetamines by NMR Techniques", Canadian Society of Forensic Science Journal, 22:2, 195-202, https://doi.org/10.1080/00085030.198
  4. Coutts, Ronald T; Malicky, Jerry L. (1973). "The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM)". Canadian Journal of Chemistry, 1973, 51(9): 1402-1409, 10.1139/v73-210 | http://www.nrcresearchpress.com/doi/abs/10.1139/v73-210
  5. Brian A. Dawson & George A. Neville (1989) "Identification of Two New 'Designer' Amphetamines by NMR Techniques", Canadian Society of Forensic Science Journal, 22:2, 195-202, DOI: 10.1080/00085030.198 | http://www.tandfonline.com/doi/abs/10.1080/00085030.1989.10757433
  6. http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=64
  7. https://www.ncbi.nlm.nih.gov/pubmed/25217551/
  8. https://www.ncbi.nlm.nih.gov/pubmed/25553227/
  9. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
  10. http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
  11. Controlled Drugs and Substances Act (S.C. 1996, c. 19) | http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html
  12. Misuse of Drugs Act 1971 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I
  13. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
  14. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.